483 related articles for article (PubMed ID: 15855208)
1. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.
de Francisco AL
Expert Opin Pharmacother; 2005 Mar; 6(3):441-52. PubMed ID: 15794735
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
[TBL] [Abstract][Full Text] [Related]
8. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
[TBL] [Abstract][Full Text] [Related]
9. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
Sprague SM; Evenepoel P; Curzi MP; González MT; Husserl FE; Kopyt N; Sterling LR; Mix C; Wong G
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213
[TBL] [Abstract][Full Text] [Related]
16. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
[TBL] [Abstract][Full Text] [Related]
18. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
20. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
Goodman WG
Semin Dial; 2004; 17(3):209-16. PubMed ID: 15144547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]